Live from SEC Form 4, 13D/13G and 13F filings, plus clinical trials

See what company insiders are buying, minutes after they file.

When a CEO, CFO or director buys their own company's stock on the open market, they have to report it to the SEC within two business days. Insiderhedge collects every one of those filings, scores the purchases, and flags when several insiders buy at once.

See this week's top buys (free) Daily alerts & datasets
6,627Form 4 filings, last 30 days
1,298open-market insider buys
91companies with cluster buying

Top insider buys (free, 48-hour delay)

Ranked by signal score. Paid alerts and datasets get every filing within minutes. Updated Nov 05, 2026 03:11 UTC.

ScoreTickerCompanyInsiderRoleTrade dateValueHolding +Cluster
81RAPPRapport Therapeutics, Inc.Healy JamesDirector2026-10-28$20.00M51%7 insiders
79RAPPRapport Therapeutics, Inc.Ignelzi Troy A.CFO2026-10-21$144K55%7 insiders
75RAPPRapport Therapeutics, Inc.Paul Steven MDirector2026-10-22$974K86%7 insiders
70ASPEAspen Neuroscience, Inc.Arch Venture Partners Xiv, L.P. / Arch Venture Partners Xiv, Llc / Arch Venture Fund Xiv, L.P. / Berns Paul L10% Owner2026-11-02$18.00Mnew4 insiders
70ASPEAspen Neuroscience, Inc.Arch Venture Fund X, L.P. / Arch Venture Fund X Overage, L.P. / Arch Venture Partners X, L.P. / Arch Venture Partners X Overage, L.P. / Arch Venture Partners X, Llc / Crandell Keith / Burow Kristina /10% Owner2026-11-02$18.00Mnew4 insiders
69RAPPRapport Therapeutics, Inc.Healy JamesDirector2026-10-28$134K55%7 insiders
68STCSTEWART INFORMATION SERVICES CORPEppinger Frederick HCEO2026-10-26$133K2%5 insiders
68NPBNORTHPOINTE BANCSHARES INCWilliams Charles Alan / Charles A Williams Tr Charles A Williams TrustCEO2026-10-23$771K2%4 insiders
68NPBNORTHPOINTE BANCSHARES INCWilliams Charles Alan / Charles A Williams Tr Charles A Williams TrustCEO2026-10-26$766K2%4 insiders
67ACNAccenture plcSweet Julie SpellmanCEO2026-10-26$2.49M26%2 insiders

See the full free list →

Latest activist and 5% stakes (free, 48-hour delay)

New Schedule 13D stakes (activists), big 13D changes and new 13G stakes of 5% or more.

FiledWhatTickerCompanyHolderStakeChangeFiling
2026-10-29New 13D stakeLUDGLUDWIG ENTERPRISES, INC.FOXO TECHNOLOGIES INC.74.90%SEC
2026-10-26New 13D stakeALDSAPPlife Digital Solutions IncMammoth Crest Capital LLC57.40%SEC
2026-11-02New 13D stakeNARANarragansett Bancorp, Inc.Narragansett Financial Corporation55.00%SEC
2026-10-28New 13D stakeNEWHNewHydrogen, Inc.SunHydrogen, Inc.42.70%SEC
2026-10-22New 13D stakeAACGATA Creativity GlobalEVERRISE HOLDINGS LLC34.51%SEC
2026-10-20New 13D stakeTEGOTEG OVERSEASIrodakhon Abduvakhitova31.14%SEC
2026-10-26New 13D stakeCTYCity Therapeutics, Inc.ARCH Venture Fund XII, L.P.25.60%SEC
2026-10-21New 13D stakeFLSCFrazier Life Sciences Acquisition Corp. IIFrazier Life Sciences Holdings II LLC20.50%SEC

See all recent stakes →

What institutions bought in Q2 2026

Stocks with the most institutions opening new positions minus those selling out, from Form 13F filings.

TickerCompanyInstitutionsNewSold outValue heldShares held
INTCINTEL CORP3,5941,082115$474.22B+6%
MUMICRON TECHNOLOGY INC3,929989122$967.11B+1%
AMDADVANCED MICRO DEVICES4,027944138$649.96B+8%
MRVLMARVELL TECHNOLOGY INC2,238778113$198.82B-3%
SNDKSANDISK CORP1,83572793$240.33B-3%
AMATAPPLIED MATERIALS INC3,531673119$455.07B+3%
DELLDELL TECHNOLOGIES INC2,154605109$97.03B-5%
STXSEAGATE TECHNOLOGY HLDNGS PL1,97055867$176.27B-1%

See institutional buying and selling →

Upcoming biotech readouts

Phase 3 trials of listed companies whose main result is due soon, from ClinicalTrials.gov.

Primary completionTickerCompanyDrugConditionPhasePatientsStatusTrial
2026-11 (est.)ABBVAbbVie Inc.Upadacitinib 15mg DoseAtopic DermatitisPhase 3184Enrollment completeNCT06389136
2026-11 (est.)IMUXImmunic, Inc.IMU-838 tabletsMultiple SclerosisPhase 31,121Enrollment completeNCT05134441
2026-11 (est.)IMUXImmunic, Inc.IMU-838 tabletsMultiple Sclerosis, Relapsing-RemittingPhase 31,100Enrollment completeNCT05201638
2026-11 (est.)LLYEli Lilly & CoRetatrutideObesityPhase 3800Enrollment completeNCT06662383
2026-11 (est.)LLYEli Lilly & CoTirzepatideType 1 DiabetesPhase 3905Enrollment completeNCT06914895
2026-11 (est.)LLYEli Lilly & CoTirzepatideType 1 DiabetesPhase 3465Enrollment completeNCT06962280
2026-11 (est.)SVASinovac Biotech Ltdexperimental vaccineEpidemic MeningitisPhase 3660Enrollment completeNCT07505888
2026-11 (est.)VRCAVerrica Pharmaceuticals Inc.VP-102Common WartsPhase 3302Enrollment completeNCT07246590

See the biotech catalyst calendar →

Data & alerts

Biotech catalyst calendar: clinical trial readouts

1,198 upcoming Phase 2 and 3 readouts from 276 listed drug companies, plus every trial termination, delay and result. Refreshed daily.

$29 one-timeGet the data

Institutional holdings dataset: latest quarter (13F)

Q2 2026 13F holdings of 8,921 institutions across 23,610 securities, with every quarter-over-quarter change.

$39 one-timeGet the data

Activist and 5% stakes dataset: last 90 days

All 6,885 Schedule 13D and 13G filings from the last 90 days, with stake changes. Refreshed daily.

$29 one-timeGet the data

Insider trades dataset: last 90 days

All 20,357 Form 4 stock transactions from the last 90 days, refreshed daily.

$29 one-timeGet the data

Weekly insider buying report

235 open-market insider purchases from the week of Oct 26, scored and ranked.

$9 one-timeGet the data

Daily insider buy alerts: 30-day pass

The top-scored insider purchases and new activist stakes filed each day, in your inbox at 7 a.m. Eastern for 30 days.

$19 one-timeGet alerts

How the score works

Who boughtCEOs and CFOs count most, then presidents, chairs, officers, directors and large holders.
How muchBigger dollar purchases, and bigger increases in the insider's own holding, score higher.
Cluster buyingTwo or more insiders buying the same company within 14 days adds a strong boost.
DiscretionaryTrades under pre-scheduled 10b5-1 plans score a little lower than discretionary ones.

Weekly notes

Insider buying, week of October 26, 2026

The notable open-market insider purchases for the week of Oct 26.

Insider buying, week of October 19, 2026

The notable open-market insider purchases for the week of Oct 19.

Insider buying, week of October 12, 2026

The notable open-market insider purchases for the week of Oct 12.

Questions

Where does the data come from?

Directly from SEC EDGAR. Every Form 4 (insider trades) and Schedule 13D/13G (5%+ stakes) is read within minutes of filing, and every quarterly Form 13F (institutional holdings) as it comes in. Each row links back to the SEC.

What are 13D, 13G and 13F filings?

Anyone who acquires more than 5% of a public company must file a Schedule 13D, if they may try to influence the company (activists), or a shorter 13G if they are a passive holder. Investment managers with more than $100 million in US stocks file a Form 13F listing their holdings 45 days after each quarter ends.

What is the biotech catalyst calendar?

Every Phase 2 and 3 clinical trial run by a publicly traded drug company, from the official ClinicalTrials.gov registry, linked to its stock ticker. The primary completion date is when a trial's main result is measured; companies usually announce topline results within weeks to a few months of it. We also flag trials that are stopped, delayed or post results.

Is this investment advice?

No. We report what public filings show. Insiders buy for many reasons, and a high score is not a prediction. Do your own research.

Is it a subscription?

No. Every purchase is a one-time payment. The alerts pass runs for 30 days, and we remind you before it ends.

Who runs Insiderhedge?

An AI system operated by Datahedge LLC, with automated checks and a person handling refunds and anything unusual. Email hello@insiderhedge.com.